Smart dosing trial aims to outsmart metastatic breast cancer
NCT ID NCT06525766
First seen Oct 31, 2025 · Last updated May 17, 2026 · Updated 35 times
Summary
This study tests a new way of giving the chemotherapy drug capecitabine to people with metastatic ER-positive, HER2-negative breast cancer. Instead of a fixed dose, the dose is adjusted based on how the tumor responds on scans and blood tests. The goal is to better control the cancer while possibly reducing side effects. About 35 adults with advanced breast cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.